Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31393128 | 0.87 | RET (0.36) | RETATRRXRARXRBRXRG | |
| SCHEMBL14722631 | 0.86 | RET (0.39) | RETATRRXRARXRBRXRG | |
| SCHEMBL14723265 | 0.82 | RET (0.36) | RETATRRXRARXRBRXRG | |
| SCHEMBL29233750 | 0.80 | ATR (0.36) | RETATRRXRARXRBRXRG | |
| SCHEMBL31393200 | 0.78 | RXRA (0.34) | RETRXRARXRBRXRGCYP4F2 | |
| SCHEMBL5616694 | 0.78 | RET (0.38) | RETATRRXRARXRBRXRG | |
| SCHEMBL31190705 | 0.77 | CYP4F2 (0.35) | RETRXRARXRBRXRGCYP4F2 | |
| SCHEMBL31393059 | 0.77 | RET (0.35) | RETRXRARXRBRXRGCYP4F2 | |
| SCHEMBL24802947 | 0.74 | CYP4F2 (0.36) | RETATRRXRARXRBRXRG | |
| SCHEMBL31393087 | 0.74 | RET (0.35) | RETRXRARXRBRXRGCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | RET 97/4885ATR 128/4885RXRA 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.